Compare LPLA & DXCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LPLA | DXCM |
|---|---|---|
| Founded | 1989 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8B | 27.8B |
| IPO Year | 2010 | 2005 |
| Metric | LPLA | DXCM |
|---|---|---|
| Price | $273.47 | $73.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 21 |
| Target Price | ★ $404.14 | $85.33 |
| AVG Volume (30 Days) | 961.9K | ★ 6.4M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | N/A | ★ 47.18 |
| EPS | ★ 4.43 | 0.51 |
| Revenue | ★ $16,989,479,000.00 | N/A |
| Revenue This Year | $26.38 | $14.46 |
| Revenue Next Year | $13.53 | $12.31 |
| P/E Ratio | ★ $60.17 | $141.62 |
| Revenue Growth | ★ 37.18 | N/A |
| 52 Week Low | $260.15 | $54.11 |
| 52 Week High | $402.98 | $89.07 |
| Indicator | LPLA | DXCM |
|---|---|---|
| Relative Strength Index (RSI) | 35.00 | 69.44 |
| Support Level | N/A | $73.47 |
| Resistance Level | $381.63 | $74.08 |
| Average True Range (ATR) | 12.23 | 2.75 |
| MACD | -2.97 | 1.23 |
| Stochastic Oscillator | 26.74 | 99.63 |
LPL Financial is the largest US independent broker-dealer, with more than 32,000 financial advisors affiliated with its platform and roughly 11 million customer accounts at the end of 2025. The firm earns the bulk of its profit from interest income earned on client cash balances and from advisory fees and commissions tied to the $2.4 trillion in assets under management or advisory on its platform at year-end 2025. LPL specializes in the provision of turnkey wealth management services for affiliated independent advisors, but maintains a diverse array of affiliation modalities, running the gamut from more traditional employee models to a pure RIA custody approach. It earns tuck-in revenue from recordkeeping fees and the provision of software tools and services to its advisor base.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.